Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: An analysis using the propensity score

Hepatology International

Volumn 6, Issue 4, 2012, Pages 744-752

  Ebinuma, Hirotoshi ^a   Saito, Hidetsugu ^a   Tada, Shinichiro ^a   Nakamoto, Nobuhiro ^a   Ohishi, Tazuko ^a   Tsunematsu, Satoshi ^a,b   Kumagai, Naoki ^c   Tsuchimoto, Kanji ^d   Tsukada, Nobuhiro ^e   Inagaki, Yasutaka ^f   Horie, Yoshinori ^g   Takahashi, Masahiko ^h   Atsukawa, Kazuhiro ^a   Okamura, Yukishige ^a   Kanai, Takanori ^a   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY   (Japan)

^b KITASATO INSTITUTE HOSPITAL   (Japan)

^c SAISEIKAI CENTRAL HOSPITAL   (Japan)

^d Nihon Kohkan Hospital   (Japan)

^e Public Interest Foundation Corporation Life Extension Laboratory Attached Eiju General Hospital   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^g Hiratsuka City Hospital   (Japan)

^h Sanokousei Hospital   (Japan)

Author keywords

Chronic hepatitis C; Propensity score; Ribavirin adherence; The combination treatment of peginterferon and ribavirin; The elderly patients

Indexed keywords

HEMOGLOBIN; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY WEIGHT; CHILD; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ERYTHROCYTE COUNT; FEMALE; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPENSITY SCORE; SCHOOL CHILD; THROMBOCYTE COUNT; TREATMENT DURATION; TREND STUDY; VIRUS LOAD;

EID: 84874113827     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-011-9312-9     Document Type: Article

References (33)

1. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001;358:958-965
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982
3. Saito H, Tada S, Ebinuma H, et al. Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections. J Clin Microbiol 2006;44:3562-3568
4. Saito H, Ebinuma H, Ojiro K, et al. On-treatment predictions of success in peg-interferon/ribavirin treatment using a novel formula. World J Gastroenterol 2010;16:89-97
5. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: Projection to other countries in the foreseeable future. Oncology 2002;62
6. The 20th life table released by Ministry of Health, Labour and Welfare in Japan. http://www.mhlw.go.jp/toukei/saikin/hw/life/20th/index.html (in Japanese
7. Freeman AJ, Law MG, Kaldor JM, Dore GJ. Predicting progression to cirrhosis in chronic hepatitis C virus infection. J Viral Hepat 2003;10:285-293
8. Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29:1124-1130
9. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk of hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 1999;131: 174-181
10. Arase Y, Ikeda K, Suzuki F, et al. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Interviology 2007;50:16-23
11. Imai Y, Kasahara A, Tanaka H, et al. Interferon therapy for aged patients with chronic hepatits C: Improved survival in patients exhibiting a biochemical response. J Gastroenterol 2004;39: 1069-1077
12. Yoshida H, Arakawa Y, Sata M, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002;123:483-491
13. Buti M, Medina M, Casado MA, et al. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther 2003;17:687-694
14. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-1838
15. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-1850
16. Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007; 132:1270-1278
17. Honda T, Katano Y, Shimizu J, et al. Efficacy of peginterferon-a-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C. Liver Int 2010;30:527-537
18. Sezaki H, Suzuki F, Kawamura Y, et al. Poor response to pegylated interferon and ribavirin in older woman infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci 2009;54:1317-1324
19. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000;31:211-218
20. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55
21. Tsukiyama-Kohara K, Yamaguchi K, Maki N, et al. Antigenicities of Group I and II hepatitis C virus polypeptides-molecular basis of diagnosis. Virology 1993;192:430-437
22. Okamoto H, Kobata S, Tokita H, Inoue T, Woodfield GD, Holland PV, Al-Knawy BA, Uzunalimoglu O, Miyakawa Y, Mayumi M. A second-generation method of genotyping hepatitis C virus by the polymerase chain reaction with sense and antisense primers deduced from the core gene. J Virol Methods 1996;57:31-45
23. Parsons LS. Reducing bias in a PSMM sample using greedy matching techniques. In Proceedings of the 26th Annual SAS Users Group International Conference, Cary, NC, SAS Institute, 2004
24. Shirakawa H, Matsumoto A, Joshita S, et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008;48:1753-1760
25. Akuta N, Suzuki F, Kawamura Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and lowdensity lipoprotein cholesterol levels. J Hepatol 2007;46:403-410
26. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-1109
27. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401
28. Azakami T, Hayes CN, Sezaki H, et al. Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy. J Med Virol 2001;83:1048-1057
29. Horiike N, Masumoto T, Nakanishi K, et al. Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol 1995;10:246-249
30. Hayes CN, Kobayashi M, Akuta N, et al. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 2011;60:261-267
31. Iwasaki Y, Ikeda H, Araki Y, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006;43:54-63
32. Hiramatsu N, Oze T, Tsuda N, et al. Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy? Hepatol Res 2006;35:185-189
33. Antonucci G, Longo MA, Angeletti C, et al. The effect of age on response to therapy with peginterferon alfa plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 year. Am J Gastroenterol 2007;102:1383-1391